

Remarks

Currently Claims 1-14 are pending.

The specification has been amended to recite the claim of priority and to include an abstract on a separate page.

Claims 1, 3 and 5 are amended herein. Claim 1 is amended to change "can be" to "is" for the purpose of correcting grammar. Claims 3 and 5 are amended to remove multiple dependencies for the purpose of reducing claim fees and to remove a redundant phrase. Claim 5 is further amended to rewrite a "human" subject as new claim 6. The foregoing amendments do not narrow the scope of the claims and are not made for purposes of patentability. No new matter is added.

New claims 6-14 are added. Support for these claims can be found throughout Applicants' original application, including at original claims 1-5 and page 12, lines 15-22 of the specification.

Applicant respectfully submits that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at 919 483-8222, to discuss this case further if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 8 February, 2005
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988